Additionally, the CARDAPAC (Physical Activity Intervention on Myocardial Function in Patients with HER2 + Breast Cancer) (NCT02433067) study is exploring the impact of individualized exercise interventions (45 min, 3 days a week) in breast cancer patients treated with trastuzumab on LVEF, body composition, muscle function, metabolic, hormonal and inflammatory responses, pain, fatigue, and quality of life. The gene discussed is ERBB2; the disease is breast cancer.